Dysautonomia and Non-Motor Complications in Parkinson's Disease — MDS 2026
The MDS 2026 Congress features extensive programming on autonomic dysfunction and non-motor complications in Parkinson's disease, reflecting the growing recognition that these symptoms significantly impact quality of life and often precede motor signs by years or decades.
Autonomic Dysfunction in PD
Mermaid diagram (expand to render)
Cardiovascular Dysregulation
Orthostatic Hypotension
Orthostatic hypotension (OH) affects 30-50% of PD patients and represents a major cause of morbidity[@oh2024]:
| Feature | Details |
|---------|---------|
| Definition | ≥20 mmHg systolic or ≥10 mmHg diastolic drop within 3 minutes of standing |
| Prevalence | 30-50% of PD patients |
| Pathogenesis | Central autonomic network degeneration, norepinephrine deficiency |
| Symptoms | Lightheadedness, syncope, falls, postprandial worsening |
| Management | Volume expansion, compression garments, midodrine, droxidopa |
MDS 2026 Key Insights:
- OH may be the presenting symptom in up to 10% of PD patients
- Supine hypertension complicates management in 50% of OH patients
- Baroreflex failure precedes cardiac sympathetic denervation
- Non-dopaminergic medications (midodrine, droxidopa) preferred to avoid motor worsening
Supine Hypertension
- Present in 50% of PD patients with OH
- Contribute to nocturnal supine renal sodium loss
- Management: bedtime clonidine, bedtime losartan, elevate head of bed
Heart Rate Variability
- Reduced HRV predicts faster disease progression
- Cardiac sympathetic denervation measured via 123I-MIBG scintigraphy
- Correlates with Braak stage 1-2 (enteric/medullary involvement)
Gastrointestinal Dysfunction
Constipation
Constipation affects 60-80% of PD patients and may precede motor symptoms by decades[@constipation2024]:
| Aspect | Details |
|--------|---------|
| Prevalence | 60-80% |
| Rome Criteria | <3 bowel movements/week, straining, incomplete evacuation |
| Pathogenesis | [Alpha-synuclein](/proteins/alpha-synuclein) deposition in ENS, Lewy bodies in myenteric plexus |
| Colon transit time | Delayed by 2-3x normal |
| Treatment | Fiber, osmotic laxatives, prokinetics, lubiprostone |
Braak Hypothesis Connection:
- Enteric nervous system (ENS) is among the earliest sites of α-syn pathology
- α-Synuclein in submucosal and myenteric neurons precedes CNS involvement
- GI dysfunction may provide biomarkers for prodromal PD detection
Gastroparesis
- Delayed gastric emptying in 30-50%
- Contributes to levodopa malabsorption ("delayed-on" phenomenon)
- Management: domperidone, erythromycin, dietary modifications
Sialorrhea (Excessive Drooling)
- Affects 30-50% of PD patients
- Due to reduced swallow frequency, not increased production
- Treatment: anticholinergics, botulinum toxin to salivary glands
Urinary Dysfunction
Urinary dysfunction occurs in 45-70% of PD patients, primarily as detrusor overactivity[@urinary2024]:
| Type | Prevalence | Mechanism |
|------|------------|------------|
| Urgency/Frequency | 45-70% | Detrusor overactivity from basal ganglia inhibition loss |
| Nocturia | 60-80% | Combination of OH, sleep fragmentation, detrusor overactivity |
| Incomplete emptying | 20-30% | Urethral sphincter bradykinesia |
Management:
- Anticholinergics: solifenacin, tolterodine (watch cognitive side effects)
- Beta-3 agonists: mirabegron
- Intermittent catheterization for retention
Sexual Dysfunction
- Erectile dysfunction: 50-70% of male PD patients
- Reduced libido: 40-60%
- Contributors: autonomic dysfunction, depression, medication effects
Sudomotor Dysfunction
- Anhidrosis or hyperhidrosis in 30-50%
- May present as patchy sweating patterns
- Correlates with disease severity
Sleep Disorders in PD
REM Sleep Behavior Disorder
RBD affects 50-60% of PD patients and is a strong predictor of synucleinopathy[@rbd2025]:
| Feature | Details |
|---------|---------|
| Prevalence | 50-60% in established PD |
| Core criteria | REM sleep without atonia, dream enactment behaviors |
| Polysomnography | REM sleep without atonia + ≥5/80% tonic chin EMG activity |
| Disease association | 80-90% develop parkinsonism or dementia within 10-15 years |
Pathophysiology:
- Subcoeruleus nucleus degeneration (PPTg, SLD)
- Loss of glycinergic/GABAergic inhibition of motor neurons
- Earlier onset RBD predicts more aggressive α-syn pathology
Treatment:
- Clonazepam: 0.25-1.0 mg HS (most effective)
- Melatonin: 3-12 mg HS (better tolerated)
- Bed safety measures
Insomnia
- Prevalence: 60-90%
- Causes: nocturnal akinesia, depression, medication effects, RBD
- Management: sleep hygiene, timed levodopa dosing, cognitive behavioral therapy
Excessive Daytime Sleepiness
- Prevalence: 30-50%
- Evaluation: Epworth Sleepiness Scale, MSLT
- Contributors: medications (dopaminergics, antidepressants), nocturnal sleep disruption
Restless Legs Syndrome
- Prevalence: 15-20% (vs 5-10% in general population)
- Improvement with dopaminergic therapy
- Differential diagnosis from akathisia
Neuropsychiatric Complications
Depression
Depression affects up to 50% of PD patients and is the most common neuropsychiatric symptom[@depression2024]:
| Feature | Details |
|---------|---------|
| Prevalence | 30-50% |
| Timing | Can precede motor symptoms by years |
| Presentation | Anhedonia, guilt, apathy vs somatic symptoms |
| Treatment | SSRIs (citalopram, sertraline), SNRIs, CBT |
MDS 2026 Updates:
- Depression correlates with dorsal raphe and locus coeruleus pathology
- Neurochemical basis: serotonin and norepinephrine depletion
- Tricyclic antidepressants may worsen OH
Anxiety
- Prevalence: 25-40%
- Often co-occurs with depression
- Can manifest as panic attacks, generalized anxiety, or social phobia
- Related to "off" periods and motor fluctuations
Psychosis
Parkinson disease psychosis (PDP) affects 20-40% of patients[@pd psychosis2025]:
| Feature | Details |
|---------|---------|
| Prevalence | 20-40% (all parkinsonism), 50-60% (PDD) |
| Core symptoms | Visual hallucinations, delusions, misidentifications |
| Risk factors | Age, disease duration, cognitive impairment, dopaminergic meds |
| Pathology | Lewy body pathology in ventral temporal cortex, limbic system |
Management Approach:
Reduce antiparkinsonian medications (gradual, prioritize dopaminergic)
Pimavanserin (FDA-approved for PDP): 5-HT2A inverse agonist
Quetiapine: first-line off-label (sedation, metabolic effects)
Clozapine: most effective but requires weekly WBC monitoringApathy
- Prevalence: 30-50%
- Distinct from depression (anhedonia key differential)
- Associated with frontal lobe dysfunction
- Treatment: dopaminergic stimulation, behavioral interventions
Impulse Control Disorders
ICD affects 10-15% of PD patients on dopaminergic therapy[@impulse2024]:
| Disorder | Features |
|----------|----------|
| Pathological gambling | Risk-taking behaviors, financial losses |
| Compulsive shopping | Excessive, unplanned purchases |
| Binge eating | Weight gain, metabolic complications |
| Hypersexuality | Inappropriate sexual behaviors |
Risk Factors:
- Dopamine agonist use (pramipexole, ropinirole > rotigotine)
- Male sex
- Young onset
- Personal/family history of OCD or addiction
Management:
- Reduce or discontinue dopamine agonists
- Consider naltrexone (off-label)
- Behavioral therapy
Hallucinations
- Visual hallucinations most common (80-90% of psychotic episodes)
- Often insight-preserved ("les hallucinations")
- Typically begin with minor hallucinations (passage, presence)
- Progress to fully formed visual hallucinations
Cognitive Impairment
Mild Cognitive Impairment in PD
- Prevalence: 20-50%
- Types: executive, attention, memory, visuospatial
- Progression: 50-80% develop dementia over disease course
- Biomarkers: reduced CSF Aβ42, elevated tau, cortical Lewy bodies
Parkinson's Disease Dementia
| Feature | Details |
|---------|---------|
| Prevalence | 30-80% (duration-dependent) |
| Diagnostic criteria | 1 year rule (PDD vs DLB) |
| Core symptoms | Executive dysfunction, attentional fluctuations, visual hallucinations |
| Progression | Median 4-5 years from PDD onset to nursing home |
Treatment:
- Cholinesterase inhibitors: rivastigmine (FDA-approved), donepezil
- Memantine: modest benefits
- Avoid anticholinergics, benzodiazepines
Fatigue
Fatigue affects 40-70% of PD patients and is among the most disabling non-motor symptoms[@fatigue2025]:
| Aspect | Details |
|--------|---------|
| Prevalence | 40-70% |
| Types | Physical, mental, psychological |
| Relationship | Correlates with depression, sleep disorders, disease severity |
| Treatment | Exercise, sleep optimization, modafinil (off-label), caffeine |
Pain
Pain affects 40-60% of PD patients:
| Type | Description |
|------|-------------|
| Musculoskeletal | Rigidity, stiffness, arthritic pain |
| Radicular | Nerve root compression |
| Dystonic | OFF-period cramping, foot dystonia |
| Central | Burning, dysesthetic pain |
| Akathitic | Restless discomfort |
Non-Motor Symptoms Scale (NMSS)
- 30 items across 9 domains
- Validated in PD populations
- Used in clinical trials
Movement Disorder Society Non-Motor Rating Scale (MDS-NMS)
- Comprehensive assessment of non-motor symptoms
- Excellent psychometric properties
SCOPA-AUT
- 25 items covering autonomic domains
- Validated for PD
PDSS-2 (Parkinson's Disease Sleep Scale-2)
- 15 items assessing sleep quality
Management Principles
Screen systematically — Use validated tools at each visit
Treat underlying causes — Optimize dopaminergic therapy, address sleep
Pharmacologic intervention — Symptom-specific, avoid interactions
Non-pharmacologic — Lifestyle modifications, exercise, therapy
Multidisciplinary care — Neurology, psychiatry, sleep medicine, urology, GICross-Links
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Autonomic Nervous System](/entities/autonomic-nervous-system)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [REM Sleep Behavior Disorder](/mechanisms/rbd-neurodegeneration)
- [Parkinson's Disease Dementia](/diseases/parkinsons-disease-dementia)
- [Gut-Brain Axis](/mechanisms/gut-brain-axis)
- [Central Autonomic Network](/circuits/central-autonomic-network)
- [Non-Motor Symptoms in PD — MDS 2026](/events/mds-2026/parkinsons-non-motor-symptoms)
References
[Unknown, Orthostatic hypotension in Parkinson disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38413179/)
[Unknown, Gastrointestinal dysfunction in Parkinson disease (2024)](https://doi.org/10.1038/s41575-024-00923-2)
[Unknown, REM sleep behavior disorder in Parkinson disease (2025)](https://doi.org/10.1002/mds.300)
[Unknown, Urinary dysfunction in Parkinson disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38567912/)
[Unknown, Parkinson disease psychosis (2025)](https://doi.org/10.1038/s41582-025-00910-8)
[Unknown, Depression in Parkinson disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38289012/)
[Unknown, Fatigue in Parkinson disease (2025)](https://doi.org/10.3233/JPD-240123)
[Unknown, Impulse control disorders in Parkinson disease (2024)](https://doi.org/10.1016/S1474-4422(24)00245-7)